Piramal Boosts N American Capacity With Ash Stevens Deal
Executive Summary
Cash-flush Piramal Enterprises is ramping up its North American drug manufacturing operations through the purchase of Ash Stevens, a US company making high-potency active pharmaceutical ingredients, in the latest in a string of deals for the unconventional Indian group.
You may also be interested in...
Piramal Eyes 20% Pharma Stake Sale
Piramal Enterprises, one of India’s biggest conglomerates, has said it is looking to sell up to a 20% stake in its Piramal Healthcare business to raise funds for spurring growth of the division through acquisitions.
How Piramal Plans To Scale Up In Critical Care, Build On Acquisitions
Peter DeYoung, CEO of Piramal Critical Care, expects to build “profitable growth positions” from the injectable products acquired from Janssen. He is also upbeat about the commercialization prospects in Europe for intrathecal baclofen and the potential launch of the first desflurane generic in the US.
India's Piramal Adds Four Pfizer Consumer Brands Pursuing Market Lead
The consumer goods arm of Piramal Enterprises makes its third acquisition in six months, keeping up a hectic deal-making pace in its quest to be one of India’s leading OTC players.